logo/base Created with Sketch.

FibroScan® powered by CAP™

CAP is the non-invasive reference parameter used as an aid to diagnose and monitor liver steatosis.

CAP is available as an option.


Liver steatosis, why quantify it?

There is a silent epidemic of fatty liver disease in the general population, called MASLD/MASH. The main causes of fatty liver disease are excessive alcohol consumption and/or poor diet and sedentary lifestyle.

If patients remain undiagnosed and untreated, they may go on to develop irreversible cirrhosis of the liver. If treated early with diet and lifestyle changes, the disease can be reversible.

Who is at-risk of fatty liver disease?

Most patients with the presence of a metabolic syndrome.

Risk factors and predictors of MASLD

  • Type 2 diabetes 
  • Overweight and obesity
  • High cholesterol
  • High blood pressure
  • High triglycerides

Advantages of CAP™

CAP™ is unique, patented and validated for liver steatosis assessment1,2: 1,130 international and peer-reviewed articles support the use of CAP™.

CAP™ is a guiding point for doctors and patients to improve monitoring of lifestyle change and therapeutic intervention.

CAP™ is a quantitative surrogate of liver steatosis expressed in decibel per meter (db/m).

Both LSM by VCTE™ and CAP™ are measured simultaneously without lengthening the examination time.

CAP™ is available on the three FibroScan® probes (S+*, M+ and XL+).

CAP™: tried and trusted


CAP™ provides a convenient and patient-friendly method to assess lipid turnover during lifestyle and dietary interventions to combat MASLD.

Publication Arslanow et al. | Clinical and Translational Gastroenterology, 2016


Lifestyle modification improves the hepatic steatosis, and CAP™ can be used to detect the improvement of hepatic steatosis during follow-up in patients with MASLD on lifestyle modification.

Publication Paul et al. | Arq Gastroenterol, 2018


The dietary intervention has a positive impact on CAP™.

Publication Arslanow et al. | Clinical and Translational Gastroenterology, 2016

chevron chevron

*CAP™ is not available on S+ probe in all countries.

1. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
2. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.